PRF Technologies raises $10M and updates progress on biotech and energy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/15/2026
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- Oil settles $3 higher on Yanbu disruption, Saudi cargo cancellations
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Global AI stocks fall as industry chiefs call for slowing development
- Stocks tend to rise after the Fed starts to hike
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Explainer-How China is preparing for the risk of AI escaping human control
- Global AI stocks fall as industry chiefs call for slowing development
- Citi sees memory market undersupply worsening through 2031
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
July 27, 2026 8:30 AM EDTTEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (PRF, PRF Technologies or the Company) today issued a Letter to Shareholders from Efraim Cohen-Arazi, Interim Chief Executive Officer.
First-Half 2026 and Recent Highlights:
Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheetLayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing-KReported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available... More